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Studies on miRNA profiling revealed that a large number of them are significantly deregulated in human
cancers. The molecular mechanisms of this deregulation are not totally clarified, even if genetics and
epigenetics are frequently involved.
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation in the human
genome. A SNP into miRNA gene might affect the transcription of primary miRNA, its processing and
miRNA–mRNA interaction. We investigated the distribution of sequence variants of miR-146a,
miR-196a2, miR-499 and miR-149 in colorectal cancer (CRC) and their effect on miRNA expression. Each
variant was identified with HRM. For miR-499 we demonstrated a significant reduction of its expression
in CRC connected to a specific genotype.
To evaluate the epigenetic effects on miRNA genes in CRC, we investigated the influence of DNA
methylation on miR-34b, miR-34c and miR-9-1 expression. We aimed to verify the relationship between
the methylation status of these miRNA genes and their relative expression in tumor samples. For the
quantification of DNA methylation we adopted a method based on Differential High Resolution Melting
(D-HRM).
 2012 Elsevier Inc. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of 21–25 nt single-stranded
non-coding RNAs that regulate gene expression at a post-
transcriptional level. MiRNAs are transcribed as long primary
transcripts (pri-miRNAs) which are processed in the nucleus into
hairpin-shaped precursor miRNAs (pre-miRNAs) by a nuclear
complex consisting of a member of the ribonuclease III family
(RNase III) Drosha and its cofactors (DGCR8) [1,2]. Pre-miRNAs
are exported to the cytoplasm by Exportin-5 [3,4] and then pro-
cessed into 18–25 nt long mature miRNAs by RNA Dicer, which is
part of the RISC RNA-induced silencing complexes to repress gene
expression [5,6]. The mature miRNA leads RISC to regions of partial
complementarity in the 30UTR of target mRNA and triggers either
their degradation or inhibition of translation [7]. Perfect or almost
perfect complementarity to target results in the RISC-mediated
mRNA degradation, whereas the presence of fewmismatched bases
is thought to arrest translation of the mRNA by the ribosome [8].
It is assessed that there may be 1000 miRNA genes in human
genome [8–10] and that a single miRNA can bind hundreds of
mRNA targets, even if their identification is difficult because onlyll rights reserved.
hemistry, Dept. of Clinical
taly. Fax: +39 055 4271371.
.the seed sequence (about 6–8 bases) aligns with the target mRNA
30 untranslated region [11,12].
Many evidences indicate that miRNAs are involved in malignant
transformation of human cells [7] and miRNA profiling is signifi-
cantly altered in human cancer [3,9,13]. Deregulation of miRNA
expression seems to generate an important signaling cascade, since
most of them have a large number of potential mRNA targets.
Sequence variants in miRNA genes are described as mecha-
nisms that can contribute to their deregulation [14]. A mutation
or a SNP at a miRNA region might affect the transcription of miRNA
primary transcripts, their processing to mature miRNA or miRNA
target interactions [3,15]. Whereas most of the identified muta-
tions or SNPs in miRNA do not affect miRNA expression and func-
tion [3,14,16–18], in some cases SNPs are associated with loss or
reduction of miRNA expression [3].
Recently, a large number of potentially functional miRNA-
related SNPs were identified and proposed as candidate cancer bio-
markers. In this study we investigated the distribution of sequence
variants of miR-146a, miR-196a2, miR-499, miR-149, in colorectal
cancer (CRC).
In different studies were highlighted several associations
between one or more SNPs of these mRNA and cancers [19–22].
In our previous work on these four miRNAs, we found an
increased risk for NSCLC, presumably through an association with
increased miRNA expression and CG genotype of miR-146a and we
Table 1
Characteristics of patients affected by CRC.
Median age (range) 69 (39–89)
yrs
Gender
Males 87
Females 73
Stage
Duke’s 1 20
Duke’s 2 74
Duke’s 3 53
Duke’s 4 13
Localization
Cecum, Ascending Transverse, Sigmoid, Descending,
Rectum
59
101
Grading
G1 20
G2 124
G3 16
Table 2
Primers and experimental procedures for miRNA genotyping.
SNP Primers forward Primers reverse
miR-146a (rs2910164 C-G) GGGTCTTTGCACCATCTCTG TCCAGTCTTCCAAGC
miR-149 (rs2292832 C-T) GTGTCTTCACTCCCGTGCTT ACCTCTCACACCCCCT
miR-196a2 (rs11614913 C-T) TCCTCCAGATAGATGCAAAGC GAGGGTAGGAGTGG
miR-499 (rs3746444 G-A) CGGCTGTTAAGACTTGCAGTG CACCCCTTCCCCACAA
miR-34b/c GGTTGGGAATTGAAGTTTG CCCAAAAATACCAAA
miR-9-1 GTTTTTTTTATTTGGGATTAG ACAACAACAAAAACC
Fig. 1. Example of the flow-chart of D-HRM for miR 9-1. Serial dilutions of methylated D
Fluorescence of each sample was normalized as differential signal against unmethylat
concentration (%) of each dilution to generate a standard curve (Panel C).
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in an independent manner from the genotype [23].
In this paper we analyzed the distribution of the above men-
tioned polymorphic variants in patients affected by colorectal can-
cer (CRC) and possible relationships between miRNA genotypes
and expression.
Each variant was detected with HRM, while the relationship
with miRNA expression profile was evaluated with dedicated real
time RT-PCR assays.
Concerning the epigenetic mechanisms influencing miRNA
expression, we know that one-third of all human miRNA genes
has a CpG island in the upstream region and may be regulated
by DNA methylation [24]. In colorectal cancer several miRNAs
were found silenced by comparing primary colorectal cancers with
matched normal colorectal epithelium [25]. In particular miR-129-
2, miR-9-1, and miR-137 were found silenced by DNA methylation
in cancer [26]. Toyota et al. treated HCT116 colorectal cancer cells
with the demethylating agent, 5-aza-20-deoxycytidine (5-aza-dC),
and compared miRNA expression profiles between the treatedAnnealing temperature PCR (C) Range of temperature HRM (C)
TCTTCA 57 77–87
CAC 58 88–98
GAGAGG 60 80–90
AC 59 80–90
CCT 55 75–95
TCAAAC 57 70–90
NA (from 0% to 100%) were amplified and submitted to HRM dissociation (Panel A).
ed control (Panel B). Values of differential fluorescence were plotted against the
140 S. Vinci et al. /Methods 59 (2013) 138–146and the untreated cells to identify silencing of miR-34b/c by pro-
moter DNA hypermethylation [27].
Even if the relationship between promoter hypermethylation
and miRNA silencing was proved by these experiments, a direct
‘in vivo’ relationship between the density of methylation of these
miRNAs and their relative expression in tumor samples was not
previously demonstrated. To this purpose we developed a method
allowing the measurement of DNA methylation based on D-HRM
[28]. We evaluated in our CRC samples the potential influence of
DNA methylation of miR-34b, miR-34c and miR-9-1 on their
expression.
2. Materials and methods
2.1. Tissues and blood samples
CRC samples were collected from 160 patients (Table 1). During
surgical resection of colorectal cancers (CRC), one sample of tumor
tissue and the corresponding apparently normal mucosa were re-
trieved from each patient. Control tissues were taken 10 cm apart
from the neoplasia. In all cases comparable tissue samples were
processed for routine histological examination. Tissue samples
were immediately steeped in RNAlater (Qiagen Gmbh, Hilden, Ger-
many) at 4 C for 24 h and subsequently stored at-80 C until anal-
ysis. Tissues were disrupted by TissueLyser with Stainless Steel
Beads 5 mm (Qiagen) according to the manufacturer’s instructions.
DNA purification was performed with QIAcube™ and QIAamp DNA
mini Kit (Qiagen). For miRNA extraction we used mirVana™miRNA
Isolation kit (Ambion, Life Technologies, USA) according to theFig. 2. Example of the flow-chart of D-HRM for miR-34b/c. Serial dilutions of methylated
Fluorescence of each sample was normalized as differential signal against unmethylat
concentration (%) of each dilution to generate a standard curve (Panel C).manufacturer’s protocol. The concentration of DNA and total RNA
was determined with Nanodrop ND-1000 Spectrophotometer
(Thermo Scientific, DE, USA).
To compare allele distribution in the control population, we col-
lected a blood sample from 178 subjects without any evidence of
diseases, matched for sex and age with CRC patients. DNA was ex-
tracted from nucleated cells with QIAamp DNA Blood Mini kit
(Qiagen).
The study protocol was approved by the local Ethical Commit-
tee and informed consent was obtained from all patients and
healthy volunteers.
2.2. Real-time RT-PCR measurement of miRNA expression
To measure miRNA expression, 10 ng total RNA were reverse
transcribed with TaqMan Reverse Transcription Kit and assayed
by the respective TaqMan microRNA kit (miR-146a ID 000468;
miR-149 ID 000472; miR-196a2 ID 000495; miR-499 ID 001045;
miR-9-1 ID 000583; miR-34b ID 002102; miR-34c ID 000428; Ap-
plied Biosystems, Life Technologies, USA) according to manufac-
turer’s instructions. For Real-Time PCR we used an ABI PRISM
7900HT Fast PCR System (Applied Biosystems). The miR-U6B was
used as endogenous control, as already reported [29,30].
2.3. HRM for genotype identification
We evaluated allelic distribution of sequence variants in pre-
miRNA hsa-miR-146a (rs2910164 C-G); hsa-miR-149 (rs2292832
C-T); hsa-miR-196a2 (rs11614913 C-T) and hsa-miR-499DNA (from 0% to 100%) were amplified and submitted to HRM dissociation (Panel A).
ed control (Panel B). Values of differential fluorescence were plotted against the
S. Vinci et al. /Methods 59 (2013) 138–146 141(rs3746444 G-A) in tissue biopsies collected from 160 patients af-
fected by CRC and in control subjects, using HRM. We amplified
100 ng DNA in a 25 lL final volume, containing 10 Buffer,
1.5 mM MgCl2, 800 lM dNTPs, 300 nM of each primer, 1.5 lM of
SYTO9 Dye (Invitrogen, Carlsbad, CA, USA) and 1U of Taq Gold
Polymerase (Applied Biosystems). PCR was performed with an ini-
tial step at 95 C for 10 min, followed by 35 cycles for 30 s at 95 C,
30 s at the respective annealing temperatures (Table 2) and 30 s at
72 C, with a final extension at 72 C for 20 min. For HRM, samples
were initially maintained for 5 min at 95 C and 1 min at 40 C and
then submitted to specific melting profiles (Table 2) on a Rotor-
Gene 6000 (Corbett Research, Australia). Primers for HRM were se-
lected using Primer 3 software [31].Fig. 3. Examples of the measurement of methylation levels in unknown samples for
amplified and submitted to HRM dissociation, together with standards at known perc
normalized as differential signal against unmethylated control (Panel B). The measureme
For simplification, we reported in the image only four standard points (0%, 6%, 25% andTo confirm HRM results, sequencing analysis was performed
in 10% randomly selected samples. In these cases, after HRM,
samples were purified with a PCR Purification Kit (Qiagen) and
submitted to cycle sequencing with 2 lL of BigDye Terminator
Ready Reaction Mix (Applied Biosystems), 2 lL of sequencing
buffer and the same primers used in HRM but 0.8 lM in a final
volume of 10 lL. After purification with a DyeEx 2.0 Spin Kit
(Qiagen), samples were analyzed with the ABI Prism 310
Genetic Analyzer (Applied Biosystems). All sequenced samples
perfectly matched HRM genotyping. In each assay, control sam-
ples carrying the three possible sequence variant were used as
reference controls.miR-34b/c. Three pairs of CRCs (VT) and corresponding normal tissues (VS) were
entage of methylation (Panel A). Fluorescence of each sample and standard was
nts of methylation in unknowns was then extrapolated on external reference curve.
100% methylation) and a single kinetic for each unknown.
Fig. 4. Expression of miRNA-499 in CRC samples and not affected tissues. Relative
real-time RT PCR in 160 CRCs and paired not affected tissues. All experiments were
performed in duplicate.
142 S. Vinci et al. /Methods 59 (2013) 138–1462.4. Quantitative evaluation of DNA methylation in miR-34b/c and
miR- 9-1 genes by D-HRM protocol
The miR-34b and miR-34c genes are respectively located within
intron 1 and exon 2 of the same sequence on chromosome 11q23
and the two miRNAs are processed from a single primary transcript
[32,33]. Hsa-miR-9 is located on chromosome 1q22, at 183 bp of a
CpG island [26]. The two miRNAs were demonstrated to be epige-
netically regulated [27]. Using Methyl Primer Express v1.0
(www.appliedbiosystems.com) and Pyro Q-CpG v 1.0.9 software
(Qiagen) we designed primers that would anneal externally to
potentially methylated cytosines (Table 2).
We performed analysis of DNA methylation of miR-34b/c, miR-
9-1 by D-HRM as previously described [28]. For methylation anal-
ysis, 500 ng of DNA from samples and standards were treated with
sodium bisulfite using the Epitect Bisulfite Kit (Qiagen). Modified
DNA was immediately submitted to D-HRM and was stored at
20 C. PCR was performed in 12.5 lL final volume, containing
1 Buffer, 3.5 mM MgCl2, 800 lM dNTPs, 600 nM of each primer,
1.5 lM of SYTO9 Dye (Invitrogen, CA, USA) and 1U of Taq Gold
Polymerase (Applied Biosystems) and 1 lL of DNA treated with
bisulfite was amplified. For miR-34b, 2.5 mM MgCl2 was used to
increase amplification efficiency. PCR was performed with an ini-
tial step at 95 C for 10 min, followed by 35 cycles for 30 s at
95 C, 30 s at the specific annealing temperature (57 C for miR-
9–1, 55 C for miR-34b/c) and 30 s at 72 C, final extension at
72 C for 20 min. For the HRM, performed on a RotorGene 6000
(Corbett Research, Sydney, Australia), samples were initially main-
tained for 5 min at 95 C, for 1 min at 40 C and then submitted to
specific melting profiles.
For each experiment, CpG Genome Universal Methylated and
Unmethylated DNA (Chemicon International Inc.) were used as po-
sitive (100% methylated) and negative (0% methylated) controlsTable 3
Median (min and max) of miR-499 expression in CRC samples and normal tissue.
miR-146a miR-149
CRC 73.9 0.32
(0.04–10,297) (0.0001–8
Normal tissue 71.4 1.52
(1.1–17,559) (0.01–388
p 0.295 0.578and mutually diluted to generate a 7 points external reference
curve with decreasing percentage of DNA methylation (100%,
50%, 25%, 12,5%, 6,25%, 3,12% and 0%).
Melting curves were normalized using the HRM software and a
differential profile was then evaluated for each sample by compar-
ing fluorescence at the melting point against the value of fluores-
cence of the negative control (unmethylated DNA). The values of
differential fluorescence (DF) for each point of reference curve
were graphically plotted to generate a linear response with stan-
dards containing a growing percentage of methylated DNA (Fig. 1
and Fig. 2). The evaluation of methylation levels in unknown sam-
ples was calculated by extrapolation of DF on respective external
reference curve (Fig. 3). All experiments were performed in
duplicate.
2.5. Statistical analysis
Statistical analysis (T-Test and Anova) were carried out using
the SPSS software package. The associations between miRNA poly-
morphisms and CRC risk were estimated by odds ratios (OR) and
their 95% confident intervals (95% CI).
3. Results
3.1. Expression of miR-146a, miR-149, miR-196a2 and miR-499 in
cancer tissues and paired not affected tissues
The relative expression of the four miRNAs was determined in
all CRC samples and compared with levels in paired not affected
tissues. The expression of miR-146a, miR-149 and 196a2 did not re-
veal significant differences between normal and affected tissues. In
particular, for miR-146a, the median and minimum and maximum
were 73.9 (0.04–10297) in the CRC vs. 71.4 (1.1–17559) in the nor-
mal tissue; formiR-149were 0.32 (0.0001–89.4) in the CRC vs. 1.52
in the normal tissue (0.01–388); for miR-196a2 were11.72 (0.04–
1176)) in the CRC vs. 8.60 (0.01–1097) in the normal tissue.
On the contrary, we found a significant decrease (p < 0.05) of
miR-499 expression in cancers when compared to paired unaf-
fected tissues, as reported in Fig. 4 and Table 3.
3.2. Allele distribution of miR-146a, miR-149, miR-196a2 and miR-499
genes genotype and miRNA expression
The application of HRM allowed the correct genotyping to all
our samples. In the case of miR-149, miR-196a2 and miR-499 this
was obtained by the direct comparison of dissociation profiles that
easily discriminated the three possible genotypes. For miR-146a
(C > G), the discrimination between CC and GG samples was not
obtained in our experimental conditions, whereas heterozygote
CRC was easily identified. To discriminate the homozygotes a sec-
ond PCR was performed in which samples was mixed 1:1 with a
standard CC sample, obtaining a GC profile for GG samples, while
those with the CC genotype have an unchanged profile.
Examples of dissociation curves for sample screening are re-
ported in Fig. 5.miR-196a2 miR-499  1000
11.72 0.85
9.4) (0.04–1176) (0.01–869.3)
8.6 1.48
) (0.01–1097) (0.01–1000)
0.128 0.05
Fig. 5. Examples of plot genotyping of 4 miRNAs obtained by HRM. For miR-146a (rs29101164 C > G), the discrimination between CC and GG samples was not directly
obtained in our experimental conditions, whereas heterozygote CRC were easily identified. To discriminate the homozygotes, a second PCR was performed in which samples
was mixed 1:1 with a standard CC sample, obtaining a GC profile for GG samples, while those with the CC genotype have an unchanged profile (Panels A and B). Genotypes of
miR-149 (rs2292832 T > C), miR-196a2 (rs11614913 C > T) and miR-499 (rs3746444 G > A) were accurately evaluated by a single HRM experimental profile (see Panels C, D
and E, respectively).
Table 4
Allelic frequency and genotype of miRNA in patients affected by CRC (n = 160) and control subjects (n = 178).
miR Genotype CRC n (%) Controls n (%) OR 95% CI p
miR-146a (rs2910164 C-G) GG 86 (53.8) 100 (56.2) 1 0.521
CG 57 (35.6) 65 (36.5) 1.015 0.64–1.60 0.218
CC 17 (10.6) 13 (7.3) 0.681 0.31–1.48 0.264
[G] vs. [C] [229] vs. [91] [265] vs. [91]
miR-149 CC 79 (49.4) 86 (48.3) 1 0.285
(rs2292832 C-T) TC 58 (36.2) 75 (42.1) 1.176 0.74–1.87 0.138
TT 23 (14.4) 17 (9.6) 0.628 0.31–1.29 0.278
[C] vs. [T] [216] vs[104] [247] vs. [109]
miR-196a2 (rs11614913 C-T) CC 62 (38.8) 83 (46.6) 1 0.092
CT 86 (53.8) 84 (47.2) 0.721 0.46–1.13 0.156
TT 12 (7.4) 11 (6.2) 0.587 0.25–1.38 0.073
[C] vs. [T] [210] vs. [110] [250] vs. [106]
miR-499 AA 93 (58.1) 105 (59.0) 1 0.076
(rs3746444 G-A) AG 32 (20.0) 56 (31.5) 0.663 0.39–1.11 0.001
GG 35 (21.9) 17 (9.5) 2.931 1.49–5.77 0.01
[A] vs. [G] [218] vs. [102] [266] vs. [90]
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evaluated by HRM in CRC patients as well as in the group of 178
control subjects are reported in Table 4. All sequenced samples
perfectly matched HRM genotyping. For miR-146a, miR-149,miR-196a2 we did not detect any significant difference in allele
distribution between the two groups. Conversely, we were able
to demonstrate that for miR-499 showed a significant difference
for genotype distribution. In particular GG frequency was signifi-
Fig. 6. Expression of miR-499 in CRC samples according genotype. Relative
expression of miR-499 in CRC samples stratified according genotype distribution
All experiments were performed in duplicate.
Fig. 7. Expression of miR-34b, miR-34c and miR-9-1 in CRC samples and not affected tissues. Relative real-time RT PCR in 160 CRCs and paired not affected tissues. All
experiments were performed in duplicate.
Fig. 8. Methylation of miR-34c and miR-9-1 in CRC samples and not affected tissues. The evaluation of methylation levels in unknown samples was calculated by
extrapolation of DF on respective external reference curve. All experiments were performed in duplicate.
Fig. 9. Relationship between methylation and expression of miR-9-1 in CRC
samples. Correlation between methylation density of miR-9-1 and its relative
expression.
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(9.5%) (GG vs. AA: OR = 2.93, 95% CI 1.49–5.77, p = 0.01) (Table
4). We highlighted a significant difference for miR-499 when we
had grouped the GG vs. AAAG (p = 0.05).
To understand the possible influence of SNPs on transcription of
related miRNA, we stratified their relative expression according to
respective genotype in CRC tissues. We did not find any significant
association between genotypes and expression for miR-146a, miR-
149, and miR-196a2.
On the contrary, miR-499 expression was found significantly
associated to its allelic variants, since GG genotype was connected
to a reduced expression in comparison to AA samples, whereas AG
CRC had and intermediate expression (Anova test, p = 0.022, Fig. 6).
In particular, the data concerning the miR-499 expression associ-
ated with the allelic variant showed for genotype GG a median of
0.5, minimum 0.01 and un maximum of 217.6; for AG 0.8, 0.02
and 101.5; for AA 1.8, 0.01 and 869.3.
Genotype distribution AG vs. GG of miR-499 was not statisti-
cally different.
3.3. Correlation between the expression and methylation status of the
promoter region of miR-34b/c and miR-9–1
We evaluated the expression of the 3 miRNAs in the same
paired tissues. We highlighted in all cases a reduced expression
in CRC that reached the significance for miR-34c (p = 0.019) and
miR-9-1 (p < 0.0001) (Fig. 7).
Subsequently, the analysis of the level of methylation in CRC
and normal paired tissues, obtained by D-HRM, revealed a signifi-
cant hypermethylation in tumor tissues for both miR-34b/c
(p < 0.0001) and miR-9-1 (p < 0.0001) genes (Fig. 8).
In tumor tissues, the downregulation of their expression and
increasing of promoter hypermethylation in these miRNAs, seems
to indicate the presence of an epigenetic mechanism underlying
their regulation. To confirm this inverse relationship we evaluated
their reciprocal linearity. In the case of miR-9-1 we detected a sig-
nificant (p = 0.002) negative relationship, showing that the pro-
gressive increase of methylation density correspond to a weak
reduction of miRNA expression (Fig. 9).
4. Discussion
A great number of studies on miRNA profiling demonstrated
that they are distinctively and differentially expressed in cancerFig. 10. Relationship between methylation and expression of miR-34b and miR-34c in C
their relative expression.tissues as compared with normal adjacent tissues [9]. Genetic
and epigenetic mechanisms seem to have an influence on miRNA
deregulation in cancers even if these aspects are only partially clar-
ified [34].
A single nucleotide replacement resulting from amutation or an
SNP can be involved in deregulation of miRNA expression [32,35–
37]. Some studies indicated the association of SNPs in miR-146a,
miR-196a2, miR-149 and miR-499 with variable risk in cancers
[38,21,39–41].
For this reason, we evaluated the genotype distribution of the
four miRNAs in 160 CRC patients. We could not able to identify
any association between genotypes and cancer risk for miR-146a,
miR-196a2, and miR-149. In addition, using relative RT-PCR we
could not find differential expression between normal mucosa
and affected tissues for the three miRNAs.
However we demonstrated that the expression of miR-499 is
significantly down-regulated in CRC (p < 0.05). In addition, the
evaluation of genotype distribution of miR-499 in the cancer pop-
ulation revealed a significant difference with healthy subjects. The
GG genotype was twofold more frequent (p < 0.01) in CRC patients,
with an estimated odd risk of 2.9. These results are in agreement
with those reported for breast cancer, since the authors had shown
that the variant A > G of miR-499 is associated with a significantly
increased risk of developing this cancer, with a 1.75 odd risk [38].
Similarly, the G allele was found to be significantly associated with
an increased risk of cervical squamous cell carcinoma [42]. Even if
both these two published studies suggested a role for the G allele
in determining an increased incidence for respective cancers, no
functional connection was previously demonstrated to support
the relationship between genotype and cancer risk. For this reason,
we evaluated the possible influence of genotypes in the regulation
of its expression by stratifying miR-499 expression according to its
allele distribution. We found that the G allele appears to be associ-
ated with a significant decrease in expression, as demonstrated by
the progressive reduction of expression in AG and, more clearly, in
GG patients (p = 0.02). This reduction, mainly associated to the
presence of the G allele, could be the reason of the increased risk
in GG patients.
We did not find any significant relationship between the
expression of single miRNAs and pathological features of CRC
patients.
The other aspect investigated in the present study was the rela-
tionship between methylation and expression of two miRNA genes
that were already known to be epigenetically down-regulated inRC samples. Correlation between methylation density of miR-34b and miR-34c and
146 S. Vinci et al. /Methods 59 (2013) 138–146CRC [26,27,43]. In these previous studies, the epigenetic modula-
tion of miR-34b/c and miR-9-1 expression was evaluated by
in vitro methods based on functional experiments on cell lines or
through qualitative detection of hypermethylated sequences in tu-
moral DNA. However, the progressive effects of this hypermethyla-
tion were not previously studied in vivo, based on the comparison
between methylation levels and miRNA expression in CRC samples
and paired not affected tissues.
To fulfil our aim, we used a quantitative and accurate method
for the estimation of D-HRM, which allows the quantification of
methylated sequences referring to an external reference curve gen-
erated by reconstituted samples with pre-defined percentage of
methylated DNA [28].
The analysis of the methylation level in CRC and normal paired
tissues revealed a significant hypermethylation in CRC tumor tis-
sues for both miR-34b/c and miR-9-1 genes.
Regarding miRNA expression, we found no difference between
normal tissues and CRC for miR-34b whereas a significant differ-
ence was found for miR-34b and miR-9-1.
The final step of the methylation study was performed to eval-
uate any linear relationship between methylation density and
expression for each miRNA. We did not find any significant corre-
lation in the case of miR-34b and miR-34c in CRC (Fig. 10). On the
other side, we detected a very low significant relationship between
methylation and expression for miR-9-1 that seems to indicate
only an hypothetical trend between methylation and expression.
In conclusion the results of our studies seem to indicate that ge-
netic effects connected to SNPs at the level of miRNA genes may
have a significant relationship with the expression and clinical fea-
tures in CRC. On the opposite, methylation seems to have limited
significance and impact on miRNA expression; according to our
data, we can conclude that methylation cannot be proposed as a
potential biomarker in CRC patients.
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